Last reviewed · How we verify
Synflorix
At a glance
| Generic name | Synflorix |
|---|---|
| Also known as | Pneumococcal conjugate vaccine GSK1024850A, Pneumococcal conjugate vaccine GSK1024850A., PHiD-CV, PHiD-CV10, 10 valent pneumococcal conjugate (vaccine) |
| Sponsor | GlaxoSmithKline |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe (PHASE3)
- The Effect of Fractional Doses of Pneumococcal Conjugate Vaccines on Immunogenicity and Carriage in Kenyan Infants (PHASE4)
- Persistence of Immunogenicity Following Reduced PCV Dosing Schedules in South African Children
- Evaluation of PCV Schedules in a Naive Population in Vietnam (PHASE4)
- Evaluation of the Non-Inferiority of a 12-Valent Pneumococcal Conjugate Vaccine in Healthy Children in Brazil. (PHASE3)
- Trial of Pneumococcal Vaccine Schedules in Ho Chi Minh City, Vietnam (PHASE2, PHASE3)
- Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSV (PHASE1, PHASE2)
- Study of 10-valent Pneumococcal Conjugate Vaccine (Pneumosil) Administered in a 2+1 Schedule to Healthy Infants (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Synflorix CI brief — competitive landscape report
- Synflorix updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI